Oxurion
Re: Oxurion
Beursblik: kleine vertraging bij Oxurion
Delen met anderen
(ABM FN) Oxurion boekt goede vooruitgang met zijn Kalahari Fase 2 studie met THR-149 voor de behandeling van diabetespatiënten met macula oedeem, maar beleggers zullen iets meer geduld moeten hebben voor de eerste studieresultaten. Dit concludeerde analist David Seynnaeve van Degroof Petercam.
Oxurion zal de eerste resultaten van deze Part B klinische studie in het vierde kwartaal publiceren. Medio december vorig jaar zei Oxurion nog dat het in de tweede helft van 2023 met resultaten zou komen. Deze kleine vertraging verraste Seynnaeve niet.
Het relatief vroege ontwikkelingsstadium van THR-149 is de reden voor het relatief lage slagingspercentage dat de bank hanteert. Degroof Petercam gaat uit van slechts 23 procent.
Vanwege het beperkt zicht hebben op de klinische prestaties van THR-149, het enige overgebleven actief van Oxurion, blijft het advies Houden. En Seynnaeve zag woensdag ook geen reden om zijn taxaties voor Oxurion aan te passen, waardoor het koersdoel 0,26 euro blijft.
Door: ABM Financial
Ben.CC liked last!
Delen met anderen
(ABM FN) Oxurion boekt goede vooruitgang met zijn Kalahari Fase 2 studie met THR-149 voor de behandeling van diabetespatiënten met macula oedeem, maar beleggers zullen iets meer geduld moeten hebben voor de eerste studieresultaten. Dit concludeerde analist David Seynnaeve van Degroof Petercam.
Oxurion zal de eerste resultaten van deze Part B klinische studie in het vierde kwartaal publiceren. Medio december vorig jaar zei Oxurion nog dat het in de tweede helft van 2023 met resultaten zou komen. Deze kleine vertraging verraste Seynnaeve niet.
Het relatief vroege ontwikkelingsstadium van THR-149 is de reden voor het relatief lage slagingspercentage dat de bank hanteert. Degroof Petercam gaat uit van slechts 23 procent.
Vanwege het beperkt zicht hebben op de klinische prestaties van THR-149, het enige overgebleven actief van Oxurion, blijft het advies Houden. En Seynnaeve zag woensdag ook geen reden om zijn taxaties voor Oxurion aan te passen, waardoor het koersdoel 0,26 euro blijft.
Door: ABM Financial
Laatste artikelen op Beursig.com
Beleggen in bitcoin en ethereum op Euronext beurs
Wild west taferelen bij aandelen, crypto valuta en ...
Volg Beursig.com
Re: Oxurion
Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LLC
Leuven, BELGIUM, Boston, MA, US – March 20, 2023 – 11:30 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 1 (A) of funding under the Subscription agreement with Atlas Special Opportunities LLC. On March 14, 2023, the Company issued 112 convertible bonds to Atlas totaling EUR 2,800,000, including EUR 800,000 in bonds for the transaction commission.
Under the terms of the Subscription Agreement, Atlas has committed to subscribe to up to EUR 20.8 million in mandatorily convertible bonds over a 24-month period at Oxurion’s discretion. The conversion price is set at an eight percent discount to the average VWAP over the three lowest days in the ten consecutive trading days prior to the conversion notice.
Tom Graney, CEO of Oxurion, said: “We appreciate Atlas’s financial support as we move forward in recruiting the final 25% of patients for the Phase 2, Part B KALAHARI trial evaluating Oxurion’s THR- 149 for treating the up to 50% of patients with diabetic macular edema (DME) for whom the current standard of care is suboptimal. Following our recent update on our recruitment progress with this trial, we look forward to potentially to demonstrate the efficacy of our therapy in addressing this large unmet need.”
emma liked last!
Leuven, BELGIUM, Boston, MA, US – March 20, 2023 – 11:30 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 1 (A) of funding under the Subscription agreement with Atlas Special Opportunities LLC. On March 14, 2023, the Company issued 112 convertible bonds to Atlas totaling EUR 2,800,000, including EUR 800,000 in bonds for the transaction commission.
Under the terms of the Subscription Agreement, Atlas has committed to subscribe to up to EUR 20.8 million in mandatorily convertible bonds over a 24-month period at Oxurion’s discretion. The conversion price is set at an eight percent discount to the average VWAP over the three lowest days in the ten consecutive trading days prior to the conversion notice.
Tom Graney, CEO of Oxurion, said: “We appreciate Atlas’s financial support as we move forward in recruiting the final 25% of patients for the Phase 2, Part B KALAHARI trial evaluating Oxurion’s THR- 149 for treating the up to 50% of patients with diabetic macular edema (DME) for whom the current standard of care is suboptimal. Following our recent update on our recruitment progress with this trial, we look forward to potentially to demonstrate the efficacy of our therapy in addressing this large unmet need.”
Re: Oxurion
Oxurion geeft krap 3 miljoen euro aan obligaties uit
Delen met anderen
(ABM FN) Oxurion heeft voor 2,8 miljoen euro aan obligaties uitgegeven als onderdeel van een overeenkomst met Atlas Special Opportunities.
Op 14 maart gaf het bedrijf 112 converteerbare obligaties uit aan Atlas voor een totaalbedrag van 2,8 miljoen euro, inclusief 800.000 euro aan obligaties voor de transactiecommissie.
Volgens de afgesloten overeenkomst heeft Atlas zich verbonden tot een financiering van maximaal 20,8 miljoen euro via converteerbare obligaties, gedurende een periode van 24 maanden.
Op de Brusselse beurs sloot het aandeel Oxurion maandag op 0,012 euro.
Door: ABM Financial
emma liked last!
Delen met anderen
(ABM FN) Oxurion heeft voor 2,8 miljoen euro aan obligaties uitgegeven als onderdeel van een overeenkomst met Atlas Special Opportunities.
Op 14 maart gaf het bedrijf 112 converteerbare obligaties uit aan Atlas voor een totaalbedrag van 2,8 miljoen euro, inclusief 800.000 euro aan obligaties voor de transactiecommissie.
Volgens de afgesloten overeenkomst heeft Atlas zich verbonden tot een financiering van maximaal 20,8 miljoen euro via converteerbare obligaties, gedurende een periode van 24 maanden.
Op de Brusselse beurs sloot het aandeel Oxurion maandag op 0,012 euro.
Door: ABM Financial
-
Beursweetjes
- Forum gebruiker
- Berichten: 102
- Lid geworden op: 24 nov 2020 11:57
- waarderingen: 34
Re: Oxurion
riday 24 March, 2023
Oxurion NV
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA
Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200 ,000 capital increase. This is part of Atlas Special Opportunities, LLC ’s EUR 20 million Capital Commitment 1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
Leuven, BE LGIUM , Boston, MA, US – March 2 4 , 2023 – 07 .00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 19,013,817 new ordinary shares on March 22, 2023, for a total amount of EUR 200,000, as the result of the conversion of 8 convertible bonds, pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.
Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 603,716,557 outstanding ordinary shares carrying voting rights (compared to 584,702,740 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
Share capital (EUR)
77,906,161.32
Total number of securities with voting rights (all ordinary shares)
603,716,557
Total number of ordinary shares (= denominator)
603,716,557
Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
694,000 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 694,000 securities carrying voting rights (all ordinary shares);
60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
976,874 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 976,874 securities carrying voting rights (all ordinary shares);
534,688 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 534,688 securities carrying voting rights (all ordinary shares);
582,248 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 582,248 securities carrying voting rights (all ordinary shares);
104 convertible bonds issued on March 14, 2023, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities, LLC on March 1, 2023; and
100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021 (as amended from time to time).
END
sanderus liked last!
Oxurion NV
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA
Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200 ,000 capital increase. This is part of Atlas Special Opportunities, LLC ’s EUR 20 million Capital Commitment 1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
Leuven, BE LGIUM , Boston, MA, US – March 2 4 , 2023 – 07 .00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 19,013,817 new ordinary shares on March 22, 2023, for a total amount of EUR 200,000, as the result of the conversion of 8 convertible bonds, pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.
Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 603,716,557 outstanding ordinary shares carrying voting rights (compared to 584,702,740 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
Share capital (EUR)
77,906,161.32
Total number of securities with voting rights (all ordinary shares)
603,716,557
Total number of ordinary shares (= denominator)
603,716,557
Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
694,000 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 694,000 securities carrying voting rights (all ordinary shares);
60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
976,874 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 976,874 securities carrying voting rights (all ordinary shares);
534,688 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 534,688 securities carrying voting rights (all ordinary shares);
582,248 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 582,248 securities carrying voting rights (all ordinary shares);
104 convertible bonds issued on March 14, 2023, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities, LLC on March 1, 2023; and
100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021 (as amended from time to time).
END
Re: Oxurion
Oxurion Publishes 2022 Annual Report
Regulated Information
Leuven, BELGIUM, Boston, MA, US – March 31, 2023 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its annual report for the financial year 2022. The annual report for the year ending December 31, 2022 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF.
https://ml-eu.globenewswire.com/Resourc ... 4d1a7473e8
https://ml-eu.globenewswire.com/Resourc ... a7bdfd8d23
VWarena liked last!
Regulated Information
Leuven, BELGIUM, Boston, MA, US – March 31, 2023 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its annual report for the financial year 2022. The annual report for the year ending December 31, 2022 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF.
https://ml-eu.globenewswire.com/Resourc ... 4d1a7473e8
https://ml-eu.globenewswire.com/Resourc ... a7bdfd8d23
